GlassScriptPhysician profile
Stephen W Halpern
NPI 1821160599
$11,379.27
in general payments reported to CMS, 2019-2025
46 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $640 · 2021: $1,131 · 2022: $1,501 · 2023: $1,916 · 2024: $2,618 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,099 · Education: $61.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,098.51 |
| Education | $61.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,221.45 | 2019-2025 | Cardiomems, 2nd Gen Centrimag Primary Console, Thoratec Heartmate 3 Lvas Implant Kit |
| Merck Sharp & Dohme LLC | $979.81 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $867.14 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Edwards Lifesciences Corporation | $672.98 | 2019-2025 | Mitris Resilia Mitral Valve, Sapien 3 Ultra Resilia, Pascal |
| Amgen INC. | $664.64 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $647.39 | 2022-2024 | Micra, Linq II |
| Janssen Pharmaceuticals, INC | $543.46 | 2019-2022 | |
| Boston Scientific Corporation | $495.39 | 2020-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $490.73 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $442.10 | 2019-2025 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $415.81 | 2019-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $412.64 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $382.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $377.68 | 2019-2025 | Jardiance |
| Pfizer INC. | $343.47 | 2019-2025 |
Show all 39 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Halpern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.